Fulgent Genetics — Third Quarter 2026 Earnings Summary

Fulgent Genetics reported third-quarter 2026 revenue of $90.4 million, representing an 8% year-over-year increase. The company recorded a GAAP net loss of $13.2 million, or $0.48 per share, while its non-GAAP net loss narrowed to $2.4 million, or $0.09 per share. Fulgent maintains its full-year 2026 revenue guidance between $330.0 million and $340.0 million and has improved its outlook for non-GAAP loss and cash positions due to disciplined spending. The company ended the quarter with $652.4 million in cash, cash equivalents, restricted cash, and marketable securities.